Stem cell transplants are not frequently offered to older patients with high-risk
The all-virtual 62nd ASH Annual Meeting & Exposition highlighted some of the newest data about Venclexta. DocWire News interviewed Tony Lin, Pharm.D., a Senior Scientific Director with AbbVie US medical affairs, to discuss this more in-depth. Dr. Lin is a
Guadecitabine (SGI-110), when given as maintenance therapy following allogeneic stem cell transplantation (allo-SCT), showed promising relapse-free survival rates (RFS) with manageable safety in high-risk patients with
December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk
Patients who underwent allogeneic bone marrow transplantation (BMT) as children were at increased risk for severe or life-threatening chronic health conditions. These findings were presented during the American Society of Hematology (ASH) 62nd Annual Meeting and Exposition.